share_log

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients With Asthma

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients With Asthma

Arrowhead Pharmaceuticals公佈了新的臨床數據,顯示ARO-RAGE在哮喘患者中實現了高水平的基因敲除
Benzinga ·  05/20 18:02

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS) 2024 International Conference. Interim results from the ongoing Phase 1/2 study demonstrate that treatment with ARO-RAGE led to a reduction in soluble RAGE (sRAGE) concentration in bronchoalveolar lavage fluid (BALF) and serum in a dose-dependent manner in normal healthy volunteers (NHV) and in patients with mild to moderate asthma.

Arrowhead Pharmicals, Inc.(納斯達克股票代碼:ARWR)今天宣佈,ARO-RAGE是一種治療哮喘等炎症性肺部疾病的在研藥物 ARO-RAGE 的新中期臨床數據,已在美國胸科學會(ATS)2024年國際會議上公佈。正在進行的1/2期研究的中期結果表明,在正常健康志願者(NHV)和輕度至中度哮喘患者中,使用ARO-RAGE治療可以以劑量依賴的方式降低支氣管肺泡灌洗液(BALF)和血清中的可溶性RAGE(sRage)濃度。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論